(1)
|
To ratify the election of each of Dr. Anna Kazanchyan and Dr. Aaron Schwartz as directors of the Company;
|
(2)
|
To appoint Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, an Independent registered public accounting firm, as the Company's independent registered public accounting firm for the year ending December 31, 2015, and authorize the Company’s board of directors to determine the compensation of the auditors;
|
(3)
|
To approve the Company’s executives and directors compensation policy;
|
(4)
|
To approve the following resolutions with regard to Dr. Dov Tamarkin, in his capacity as Chief Executive Officer of the Company:
|
|
(a)
|
grant Dr. Tamarkin a cash bonus of NIS 459,000 (equivalent to approx. $120,200, according to the representative exchange rate, published by Bank of Israel as of May 14, 2015) for the year 2014, equivalent to 85% of the maximum cash bonus of 6 monthly salaries set for him in the Company’s 2014 bonus plan;
|
|
(b)
|
increase the annual base salary of Dr. Tamarkin, to $290,000, effective January 1, 2015;
|
|
(c)
|
grant Dr. Tamarkin options to purchase 45,000 ordinary shares of the Company at an exercise price equal to the average market price of the ordinary shares during the 30 trading days prior to the grant date, vesting over 4 years in equal parts, and
|
|
(d)
|
grant Dr. Tamarkin 18,000 restricted stock units of the Company (“RSUs”), vesting over 4 years in equal parts;
|
(5)
|
To approve the following resolutions with regard to Meir Eini, in his capacity as Chief Innovation Officer of the Company:
|
|
(a)
|
grant Mr. Eini a cash bonus of NIS 459,000 (equivalent to approx. $120,200, according to the representative exchange rate, published by Bank of Israel as of May 14, 2015) for the year 2014, equivalent to 85% of the maximum cash bonus of 6 monthly salaries set for him in the Company’s 2014 bonus plan;
|
|
(b)
|
increase the annual base salary of Mr. Eini to $283,500, effective January 1, 2015;
|
|
(c)
|
grant Mr. Eini options to purchase 36,000 ordinary shares of the Company at an exercise price equal to the average market price of the ordinary shares during the 30 trading days prior to the grant date, vesting over 4 years in equal parts;
|
|
(d)
|
grant Mr. Eini 18,000 RSUs, vesting over 4 years in equal parts;
|
FOAMIX PHARMACEUTICALS LTD.
|
|||
Date: June 23, 2015
|
By:
|
/s/ Meir Eini
|
|
Name: Meir Eini
|
|||
Title: Chairman of the Board of Directors
|